Novo Nordisk Other Non-Current Liabilities 2010-2024 | NVO
Novo Nordisk other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Novo Nordisk other non-current liabilities for the quarter ending September 30, 2024 were $1.129B, a 26.05% increase year-over-year.
- Novo Nordisk other non-current liabilities for 2023 were $0.993B, a 49.51% increase from 2022.
- Novo Nordisk other non-current liabilities for 2022 were $0.664B, a 11.83% decline from 2021.
- Novo Nordisk other non-current liabilities for 2021 were $0.753B, a 8.62% increase from 2020.
Novo Nordisk Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$993 |
| 2022 |
$664 |
| 2021 |
$753 |
| 2020 |
$693 |
| 2019 |
$691 |
| 2018 |
$519 |
| 2017 |
$502 |
| 2016 |
$501 |
| 2015 |
$411 |
| 2014 |
$364 |
| 2013 |
$389 |
| 2012 |
$330 |
| 2011 |
$516 |
| 2010 |
$462 |
| 2009 |
$302 |
Novo Nordisk Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$1,129 |
| 2024-06-30 |
$1,089 |
| 2024-03-31 |
$1,047 |
| 2023-12-31 |
$993 |
| 2023-09-30 |
$896 |
| 2023-06-30 |
$865 |
| 2023-03-31 |
$773 |
| 2022-12-31 |
$664 |
| 2022-09-30 |
$750 |
| 2022-06-30 |
$688 |
| 2022-03-31 |
$700 |
| 2021-12-31 |
$753 |
| 2021-09-30 |
$682 |
| 2021-06-30 |
$687 |
| 2021-03-31 |
$731 |
| 2020-12-31 |
$693 |
| 2020-09-30 |
$703 |
| 2020-06-30 |
$673 |
| 2020-03-31 |
$680 |
| 2019-12-31 |
$691 |
| 2019-09-30 |
$632 |
| 2019-06-30 |
$511 |
| 2019-03-31 |
$531 |
| 2018-12-31 |
$519 |
| 2018-09-30 |
$521 |
| 2018-06-30 |
$523 |
| 2018-03-31 |
$523 |
| 2017-12-31 |
$502 |
| 2017-09-30 |
$494 |
| 2017-06-30 |
$538 |
| 2017-03-31 |
$518 |
| 2016-12-31 |
$501 |
| 2016-09-30 |
$431 |
| 2016-06-30 |
$423 |
| 2016-03-31 |
$402 |
| 2015-12-31 |
$411 |
| 2015-09-30 |
$357 |
| 2015-06-30 |
$354 |
| 2015-03-31 |
$309 |
| 2014-12-31 |
$364 |
| 2014-09-30 |
$408 |
| 2014-06-30 |
$365 |
| 2014-03-31 |
$367 |
| 2013-12-31 |
$389 |
| 2013-09-30 |
$383 |
| 2013-06-30 |
$329 |
| 2013-03-31 |
$326 |
| 2012-12-31 |
$330 |
| 2012-09-30 |
$324 |
| 2012-06-30 |
$347 |
| 2012-03-31 |
$375 |
| 2011-12-31 |
$516 |
| 2011-09-30 |
$507 |
| 2011-06-30 |
$456 |
| 2011-03-31 |
$458 |
| 2010-12-31 |
$462 |
| 2010-09-30 |
$351 |
| 2010-06-30 |
$305 |
| 2010-03-31 |
$308 |
| 2009-12-31 |
$302 |
| 2009-09-30 |
$274 |
| 2009-06-30 |
$246 |
| 2009-03-31 |
$237 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$481.063B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
